Repare Therapeutics logo

Repare TherapeuticsNASDAQ: RPTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

19 June 2020

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$120.73 M
-89%vs. 3y high
47%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
32%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:02:19 GMT
$2.84-$0.04(-1.39%)

Dividend

No data over the past 3 years
$2.34 M$2.73 M

Analysts recommendations

Institutional Ownership

RPTX Latest News

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
businesswire.com23 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
businesswire.com14 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
seekingalpha.com30 August 2024 Sentiment: POSITIVE

Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expected in Q4 of 2024. Preliminary RECIST response data from 10 patients using the lunresertib + camonsertib combination for ovarian and endometrial cancer patients was 50%. The global ovarian cancer market is expected to reach $11.18 billion by 2029.

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
businesswire.com10 June 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial. “Camonsertib has demonstrated a promising signal of prolonged progression free survival in patients with ATM-mutated NSCLC in our ongoing TRESR clinical trial. We are.

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
zacks.com06 June 2024 Sentiment: POSITIVE

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
businesswire.com29 May 2024 Sentiment: NEGATIVE

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29 in Munich,.

Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Zacks Investment Research20 February 2024 Sentiment: NEGATIVE

Repare Therapeutics Inc. (RPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Zacks Investment Research13 February 2024 Sentiment: POSITIVE

Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
Zacks Investment Research20 November 2023 Sentiment: POSITIVE

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

Repare: Potential Of Camonsertib With Several Shots On Goal
Seeking Alpha06 November 2023 Sentiment: POSITIVE

Repare Therapeutics presented preliminary results from the phase 1 MYTHIC study using the lunresertib and camonsertib combination for the treatment of patients with multiple solid tumor types. The biotech plans to complete the phase 1 expansion portion of the phase 1 MYTHIC study and release results in 2024. Plus, potentially initiating late-stage trials in 2024 thereafter. Highly impressive data from the lunresertib and camonsertib combination was observed in patients with gynecological tumors, where the OR was 60%.

What type of business is Repare Therapeutics?

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; cooperative research and development agreement with US National Cancer Institute to advance the development of Camonsertib; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.

What sector is Repare Therapeutics in?

Repare Therapeutics is in the Healthcare sector

What industry is Repare Therapeutics in?

Repare Therapeutics is in the Biotechnology industry

What country is Repare Therapeutics from?

Repare Therapeutics is headquartered in Canada

When did Repare Therapeutics go public?

Repare Therapeutics initial public offering (IPO) was on 19 June 2020

What is Repare Therapeutics website?

https://www.reparerx.com

Is Repare Therapeutics in the S&P 500?

No, Repare Therapeutics is not included in the S&P 500 index

Is Repare Therapeutics in the NASDAQ 100?

No, Repare Therapeutics is not included in the NASDAQ 100 index

Is Repare Therapeutics in the Dow Jones?

No, Repare Therapeutics is not included in the Dow Jones index

When was Repare Therapeutics the previous earnings report?

No data

When does Repare Therapeutics earnings report?

The next expected earnings date for Repare Therapeutics is 28 February 2025